BiomX (PHGE)
(Real Time Quote from BATS)
$0.56 USD
+0.13 (28.74%)
Updated Aug 6, 2025 12:44 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHGE 0.56 +0.13(28.74%)
Will PHGE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHGE
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BiomX Stock Gains From Favorable Study Data Presentation on BX004
PHGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PHGE
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 | ...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Tuesday's After-Market Session
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 ...